Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis by Okamoto, Takayuki et al.
Hindawi Publishing Corporation
Critical Care Research and Practice
Volume 2012, Article ID 614545, 10 pages
doi:10.1155/2012/614545
Review Article
Thrombomodulin:A Bifunctional Modulator of
Inﬂammation andCoagulation in Sepsis
TakayukiOkamoto,1 Hironobu Tanigami,2 KojiSuzuki,1,3 andMotomu Shimaoka1,2
1Department of Molecular Pathobiology and Cell Adhesion Biology, Graduate School of Medicine, Mie University,
2-174 Edobashi, Tsu 514-8507, Japan
2Department of Anesthesiology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi,
Higashinari-ku, Osaka 537-8511, Japan
3Faculty of Pharmaceutical Science, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho,
Suzuka City 513-8679, Japan
Correspondence should be addressed to Motomu Shimaoka, shimaoka@idi.harvard.edu
Received 30 September 2011; Revised 1 December 2011; Accepted 1 December 2011
Academic Editor: Edward A. Abraham
Copyright © 2012 Takayuki Okamoto et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Deregulated interplay between inﬂammation and coagulation plays a pivotal role in the pathogenesis of sepsis. Therapeutic
approaches that simultaneously target both inﬂammation and coagulation hold great promise for the treatment of sepsis.
Thrombomodulin is an endogenous anticoagulant protein that, in cooperation with protein C and thrombin-activatable
ﬁbrinolysis inhibitor, serves to maintain the endothelial microenvironment in an anti-inﬂammatory and anticoagulant state. A
recombinant soluble form of thrombomodulin has been approved to treat patients suﬀering from disseminated intravascular
coagulation (DIC)and hasthusfarshowngreatertherapeuticpotentialthanheparin. AphaseIIclinical trialiscurrentlyunderway
in the USA to study the eﬃcacy of thrombomodulin for the treatment of sepsis with DIC complications. This paper focuses on the
critical roles that thrombomodulin plays at the intersection of inﬂammation and coagulation and proposes the possible existence
of interactions with integrins via protein C. Finally, we provide a rationale for the clinical application of thrombomodulin for
alleviating sepsis.
1.Introduction
Septic shock is a leading causeof death in intensive care units
and thus represents a substantial ﬁnancial burden on the
healthcare system in Japan, in the United States, and in many
other developed nations [1, 2]. Although the mortality rate
of septic shock has tended to gradually decrease during the
past decade thanks to signiﬁcant technological advances in
supportive therapies, it remains high and eﬀective speciﬁc
treatments are still very limited [3]. Uncontrolled and sys-
temicallyspreadinginﬂammatoryresponsesthatareinitiated
by infection play critical roles in the pathogenesis of septic
shock. At sites of uncontrolled inﬂammation, endothe-
lial cells are damaged, thereby upregulating intercellular-
adhesion-molecule-1 (ICAM-1) and vascular-cell-adhesion-
molecule-1 (VCAM-1) expression, which not only enables
the accumulation of leukocytes but also heightens perme-
ability, thus leading to tissue edema formation. Damaged
endothelial cells exhibit morphological abnormalities such
as nuclear vacuolation, protrusion, and cytoplasmic frag-
mentation, thereby being subjected to the detachment from
the basement membrane [4]. Furthermore, inﬂammation
deregulates coagulation cascades, thereby inducing intravas-
cular blood coagulation at inﬂamed endothelial cells, which
reﬂects the tendency of septic shock to manifest various
coagulopathies that lead to disseminated intravascular coag-
ulation (DIC) [5].
Current consensus on septic shock pathogenesis holds
that dysregulation occurs simultaneously in both the inﬂ-
ammation and coagulation systems, thereby complicating
pathogenesis in patients and reducing the therapeutic2 Critical Care Research and Practice
eﬀectiveness of targeting either inﬂammation or coagula-
tion. A better understanding of the crosstalk that occurs
between inﬂammation and coagulation is therefore critical
to developing novel, eﬀective treatments for sepsis. Recent
investigations have shown that activated protein C (APC),
an endogenous anticoagulant protein, possesses both anti-
inﬂammatory and anticoagulant properties. A recombinant
formofAPC(Drotrecoginalfa-activated(DrotAA))hasbeen
usedinthetreatmentofseveresepticshock[6].Inthispaper,
we focus on another important endogenous anticoagulant
protein, thrombomodulin (TM). Recombinant soluble TM
(Recomodulin) has been approved in Japan in 2008 for the
treatmentofDICresultingfrominfectionandcancer[7–11].
Currently in the USA a phase II clinical trial involving sepsis
DIC patients has been completed and subsequent phase III
trials are planned. Here, we examine the basic biology of TM
with a particular emphasis on its role at the intersection of
inﬂammation and coagulation and then discuss its potential
application for septic shock.
2. Crosstalkbetween Inﬂammation and
Coagulation
Systemic inﬂammation causes the activation of the coagula-
tion cascades, and, vice versa, the players in the coagulation
cascades also possess the abilities to modulate inﬂammation
[12]. The interplays between inﬂammation and coagulation
are at the center of the pathogenesis underlying septic
shock (Figure 1)[ 5, 13]. One of the major pathways in
which inﬂammation augments blood coagulation is the
generation of thrombin mediated by tissue factor (TF) that
is upregulated on monocytes, macrophages, and endothelial
cells [14]. Endotoxin and proinﬂammatory cytokines (e.g.,
interleukin-6 (IL-6)) induce the expression of TF, which
binds to factor VII (FVII), thus forming the TF/FVIIa
complex that activates FX. FXa assembles with FVa, thereby
generating a prothrombinase complex on the surface of
endothelial cells and monocytes. This prothrombinase com-
plex converts prothrombin to thrombin, which in turn
converts ﬁbrinogen to ﬁbrin, and thereby leads to ﬁbrin for-
mation and platelet activation and aggregation. In addition,
inﬂammation impairs functions of important anticoagulant
pathways that are governed by antithrombin, protein C,
and tissue factor pathway inhibitor (TFPI). Conversely,
inﬂammation is modiﬁed by important players in coag-
ulation and anti-coagulation pathways such as thrombin,
antithrombin, thrombomodulin, and protein C as well as
ﬁbrinogen and ﬁbrin modulate inﬂammation [12]. For
example, thrombin and other activated coagulation factors
exhibit an array of proinﬂammatory activities via cleavage
activation of protease-activated receptors (PARs) [15, 16].
Thrombin induces the following: P-selectin expression in
endothelial cells, monocyte and neutrophil chemotaxis [17,
18], leukocyte adhesion molecule expression [15], IL-6 and
IL-8 production by endothelial cells [19], and lymphocyte
and monocyte activation and proliferation [20, 21].
While thrombin formation is the driving force behind
procoagulation and proinﬂammatory states, thrombin itself
remains tightly regulated and under the control of negative
feedback loops in which TM plays a critical role in tandem
with protein C (Figure 1)[ 5, 22]. The interaction of TM
with thrombin switches thrombin substrate speciﬁcity from
ﬁbrinogen to protein C [23]. Thrombin, TM, and protein
C bind simultaneously, thereby forming a complex on the
surface of the endothelium that expresses endothelial cell
protein C receptor (EPCR). During the course of complex
formation, protein C is converted to its active form: activated
PC (APC) [24]. APC subsequently dissociates from the
APC-EPCR complex and binds to protein S, in this way
forming an APC-protein S complex. The APC-protein S
complex dampens not only coagulation, by inactivating
FVa and FVIIIa, but also inﬂammation, by inhibiting the
production of inﬂammatory cytokines and the transduction
of nuclear-factor- (NF-)κB signaling in monocytes [25].
Furthermore, APC suppresses LPS-induced increases in the
pulmonary accumulation of leukocytes and in vascular
permeability [26]. Therefore, the protein C pathway plays
a pivotal role in the negative regulation of coagulation and
inﬂammation. The thrombin-TM complex also activates the
thrombin-activatable ﬁbrinolysis inhibitor (TAFI), which in
turn inhibits ﬁbrinolysis and inactivates anaphylatoxin C3a
and C5a [27, 28]. In addition to acting as a cofactor for
APC and TAFI activation, TM has exhibited a wide range
of biological activities in maintaining vascular homeostasis
(Figure 2)[ 29].
3. StructureandDomainsof Thrombomodulin
Human TM is a single-chain type 1 transmembrane gly-
coprotein measuring 557-amino acid residues long and
containing ﬁve extracellular domains (Figure 3)[ 30, 31].
The N-terminal region of TM comprises about half of the
extracellular portion of the molecule and contains a module
with a homology to other C-type lectins. Although this
domain lacks anticoagulant activity, it plays an important
role in mediating anti-inﬂammatory activities [32, 33].
The next domain of TM contains six epidermal-growth-
factor-(EGF-) like repeats that form an extended stalk in the
extracellular part of molecule. This domain showed mito-
genic activities on cultured ﬁbroblasts and vascular smooth
muscle cells. The activities were mediated via activation
of protein kinase C and mitogen-activated protein kinase
(MAPK) [34, 35]. The interaction of the EGF5-6 repeats
with thrombin has been shown to prevent the binding of
procoagulant substrates (e.g., such as FV, ﬁbrinogen) to
thrombin[36–39]. These EGF4-6 repeats are required for the
activation of protein C, while the EGF3-6 repeats are needed
for the activation of TAFI [39–41].
The third domain is a serine/threonine-rich domain
bearing potential sites for O-linked glycosylation. This
domain supports the attachment of chondroitin sulfate.
Biochemical studies have shown that chondroitin sulfate,
when attached to TM, enhanced the potency of the latter
to activate protein C [42, 43]. In addition, it accelerates
the neutralization of thrombin and facilitates the binding of
platelet factor 4 (PF4) to protein C [44]. The chondroitinCritical Care Research and Practice 3
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Figure 1: Crosstalk between inﬂammation and coagulation. Proinﬂammatory stimulation induces TF expression in monocytes,
macrophages,andendothelialcells.TFinitiatesacoagulationcascadeandtheFXa-FVacomplexconvertsthrombin.Thrombininducesﬁbrin
formation and activates platelets, monocytes, and endothelial cells through PARs. Thus, thrombin acts to form a positive feedback loop that
augments coagulation and inﬂammation. In a negative feedback loop, the thrombin-TM complex activates protein C and downregulates
coagulation and inﬂammation. APC, in tandem with its cofactor protein S, inactivates FVa and FVIIIa. In addition, the APC-EPCR complex
induces anti-inﬂammatory eﬀects through PARs. Therefore, thrombin, TM, and protein C-EPCR play pivotal roles in the crosstalk that
occurs between inﬂammation and coagulation.
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Figure 2: Multiple roles of TM in the maintenance of vascular homeostasis. TM inhibits inﬂammation, apoptosis, tumor metastasis,
thrombin function, adhesion molecule expression, and leukocyte adhesion. Proinﬂammatory high-mobility group box 1 (HMGB1) is
neutralized and degraded by TM.
sulfate moiety may strengthen the thrombin-TM binding by
interacting with the anion binding exosite of thrombin, to
which heparin binds. Of note, heparin was shown to inhibit
the thrombin-TM binding possibly by competing with the
TMchondroitinsulfatemoietyforthethrombinexosite[45].
A well-conserved transmembrane domain is typically
followed by a short cytoplasmic tail. A cysteine in the
cytoplasmic tail is thought to mediate the multimerization
of TM [46]. In human-cultured vein endothelial cells,
thrombin binding to TM induced signaling events that lead4 Critical Care Research and Practice
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Figure 3: Structure and domains of TM. TM contains an N-terminal C-type lectin-like domain, an extended stalk of six EGF modules, a
serine/threonine-richregionwithtargetsitesforposttranslationalglycosylation,atransmembranedomain,andashortcytoplasmicdomain.
EGF domains 5-6 bind thrombin. EGF4-6 is required for protein C activation and EGF3-6 for TAFI activation.
to the activation of endothelial nitric oxide (NO) synthase 3
(NOS-3) through modulation of G protein-coupled receptor
(GPCR) signals [47]. Although knockout mice completely
lacking TM died in utero due to a defect in placental
development [48], knock-in mice expressing mutant TM
that lacks the cytoplasmic domain showed no abnormalities
in fetal development, survival, and coagulation [49, 50].
Recomodulin, a recombinant form of human solu-
ble TM, comprises only the extracellular domain of TM
that includes N-terminal C-type lectin domain, EGF-like
domain, and O-glycosylation domain [51] .S i m i l a rt oa
native membrane-bound TM, rhsTM binds to thrombin
to inactivate coagulation, and thrombin-rhsTM complex
activates protein C to produce APC.
4.AnticoagulantProperties
of Thrombomodulin
TM exerts its anticoagulant activity not only by inhibiting
thrombin but also by accelerating APC generation [36, 37,
52, 53]. Upon TM binding, thrombin undergoes a reduction
in its aﬃnity to procoagulant substrates [36, 37, 52, 53].
TM directly inhibits most of the procoagulant functions
of thrombin including ﬁbrinogen clotting, platelet and EC
activation, and FV activation [36, 37]. In addition, TM accel-
erates the inactivation of thrombin via both antithrombin
and protein C inhibitor [54, 55]. TM switches thrombin
substrates speciﬁcity to protein C [23]. APC suppresses
further thrombin formation by proteolytically degrading
FVa and FVIIIa. This activity is enhanced by protein S,
the cofactor for APC (Figure 1). The anti-inﬂammatory
propertiesofTMmaybepartlyexplainedbytheconceptthat
the aﬃnity of thrombin for TM is likely much higher than
that for other factors in pro- and anticoagulant pathways
[23], potentially making TM a scavenging inhibitor of
circulating thrombin.
Inﬂammation has been reported to downregulate TM
expression [56]. Tumor necrosis factor-α (TNF-α) induces
internalization of TM via endocytosis, thereby reducing its
surface expression [57]. Such reduced TM expression at sites
of inﬂammatory injury may exacerbate blood coagulation.
Indeed, endothelium-speciﬁc deletion of TM in mice caused
spontaneous and fatal thrombosis in the arterial and venous
vessels [58], indicating that TM may play a role in preventing
intravascular thrombus formation.
5. Anti-InﬂammatoryEffects
of Thrombomodulin
5.1. APC-Dependent Mechanisms. TM has been shown to
mediate anti-inﬂammatory activities using APC-dependent
and APC-independent mechanisms, depending on the set-
ting[22].IntheAPC-dependentmechanism,TMexecutesits
anti-inﬂammatory activities by enhancing the activation ofCritical Care Research and Practice 5
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Figure 4:PotentialmolecularmechanismsbywhichAPCexecutes anti-inﬂammatoryeﬀects.(a)Caveolin-1isassociatedwithEPCRinlipid
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transactivation. Activation of S1P receptor 1 improves endothelial barrier function, thus facilitating the ability of the APC-EPCR complex
to exert anti-inﬂammatory eﬀects.
protein C. The resulting APC downregulates inﬂammatory
cytokine production by decreasing the expression of NF-κB
components and inhibiting their nuclear translocation [59–
62]. These anti-inﬂammatory eﬀects are dependent upon
APC, EPCR, and PAR-1 [63, 64]. It is thought that protein
C and/or APC binding to EPCR results in the coupling of
PAR-1 to Gi in endothelial cells (Figure 4(a))[ 65–67]. Both
PAR-1 and EPCR are known to associate with caveolin-1 in
lipid rafts or protein C- or APC-EPCR complexes, leading to
caveolin-1 dissociation from EPCR. This process appears to
favoranti-inﬂammatoryphenotypesofendothelialcells[68].
APC has been shown to enhance the endothelial bar-
rier function through transactivation of sphingosine-1-
phosphate (S1P) receptor signaling (Figure 4(b))[ 69, 70].
Improving endothelial barrier function would provide anti-
inﬂammatory eﬀects by reducing leukocyte extravasation
to sites of inﬂammation. Apolipoprotein E receptor 2
(ApoER2) and angiopoietin (Ang)/tie2 signaling pathways
havebeenshowntocontributetothecytoprotectiveandanti-
inﬂammatory properties of APC [71, 72].
In addition to acting on endothelial cells, APC has
been shown to target leukocytes. In one study, APC bound
to leukocyte integrins through an RGD motif, thereby
inhibiting neutrophil migration into inﬂamed tissues [73].
In addition, APC was shown to cleave and consequently
neutralize the cytotoxicity of extracellular histones released
from dying leukocytes [74]. Histone administration resulted
in neutrophil margination, microhemorrhage, intravascular
thrombosis, and capillary leak of ﬁbrin. Coadministration
of APC alleviated lethality of histone. By contrast, histone
toxicity was much more pronounced in mice, where the PC
pathway was blocked [74].
Reduced levels of PC were found in the majority of
patients with sepsis and were associated with higher rates of
morbidity and mortality [75, 76]. A controversial PROWESS
study showed that treatment with recombinant APC not
only lowered the plasma levels of D-dimer and IL-6 but also
reduced mortality in patients with severe sepsis [6].
5.2. APC-Independent Mechanisms. TM modulates ﬁbrinol-
ysis and inﬂammation through thrombin-activatable ﬁbri-
nolysis inhibitor (TAFI). TAFI is a circulating zymogen that
is activated by the thrombin-TM complex [77, 78]. Activated
TAFI eliminates lysine residues at the C-terminal end of
ﬁbrin,therebysuppressingtheincorporationofplasminogen
and tissue plasminogen activator (t-PA) into the ﬁbrin
clot (Figure 5). Thus, activation of TAFI by TM inhibits
ﬁbrinolysis, thereby preventing the resolution of already
formed clots. This activity complements the role of TM-
induced activated protein C to prevent the formation of new
clots, thereby balancing hemostasis [79]. While diminishing
ﬁbrinolysis by acting on ﬁbrin, activated TAFI also aﬀects
inﬂammation [77, 78]. TAFIa has been reported to act
on, and inactivate, proinﬂammatory mediators such as the
anaphylatoxins complement factors C3a and C5a [80–82],
bradykinin, and osteopontin [44, 78].
Independently of APC, TM exhibits anti-inﬂammatory
activities via the EGF domain of TM and the N-terminal6 Critical Care Research and Practice
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ability to inactivate proinﬂammatory mediators, C3a, C5a, bradykinin, and osteopontin by removing their C-terminal residues. TAFIa also
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Figure 6:APC-andTAFIa-independentanti-inﬂammatoryeﬀectsofTM.Thrombomodulinbindstothrombin,therebyblockingactivation
of protease-activated receptors. The lectin-like domain binds to, and enhances degradation of, proinﬂammatory molecule HMGB1. In
addition, the lectin-like domain is thought to bind to an unidentiﬁed receptor, thereby suppressing MAP kinase and NF-κB activation.
lectin-like domain (Figure 6)[ 22, 83]. TM binds to throm-
bin, thereby inhibiting the proinﬂammatory activities of
thrombin [16], including induction of endothelial-inducible
nitric oxide synthase expression, monocyte and neutrophil
chemotactic activity, upregulation of leukocyte adhesion
molecules, enhancement of IL-6 and IL-8 production from
endothelial cells, and mitogenic activity involving lympho-
cytes, ﬁbroblasts, macrophages, mesangial cells, neuroblas-
toma cells, and osteoblasts. Several of thrombin proin-
ﬂammatory properties are mediated via the cleavage and
activation of PARs [16]. TM binding to thrombin has been
shown to decrease PAR-1-induced activation of ERK1/2 and
to suppress the mitogenic eﬀects of thrombin [33, 84].
The anti-inﬂammatory activities of the N-terminal
lectin-likedomainarethoughttoactinanAPC-independent
manner, since this domain is dispensable to APC generation.
Mutant mice expressing TM that lacks this lectin-like
domain did not show altered in vivo APC generation [33].
However, these mice did exhibit an increased susceptibility
to endotoxin-induced sepsis. Endothelial cells isolated from
mutant mice exhibited elevated ICAM-1 expression as well
as increased ICAM-1-mediated leukocyte adhesion. In good
agreement with these ﬁndings, a soluble lectin-like N-
t e r m i n a ld o m a i no fT Mp r o v e ds u ﬃciently robust to inhibit
TNF-α-induced ERK phosphorylation and restore normal
leukocyte adhesion to mutant endothelial cells. In addition,
this recombinant lectin-like TM domain also protected
cultured endothelial cells from cell death, possibly via
modulation of NF-κBp a t h w a y s ,b u tm o r el i k e l yb ys e r u m
deprivation [33].
Another anti-inﬂammatory target of TM is high-
mobility group box 1 (HMGB1), a ubiquitously expressed
nuclear protein that is released from necrotic cells. Upon
being released, HMGB1 binds to the receptor for advancedCritical Care Research and Practice 7
glycation end products (RAGE) [85]. HMGB1-RAGE sig-
naling has been implicated in the pathogenesis and/or
progression of various clinical disorders, such as infections,
sepsis, arthritis, and cancer. The lectin-like domain of
TM interferes with HMGB1 binding to RAGE, thereby
impairing HMGB1-RAGE signaling [86]. Alternatively, TM
may antagonize HMGB1 by enhancing thrombin-mediated
proteolytic degradation of HMGB1 [87].
6. Therapeutic Application of TM
The dual ability of TM to suppress both coagulation
and inﬂammation makes this molecule a promising drug
candidate for the treatment of DIC and/or septic shock.
In order to administer it intravenously, a soluble form of
recombinant TM (rhsTM), containing only the extracellular
domains, has been developed [88]. Like the membrane-
bound native TM, rhsTM retains the ability to bind to
thrombin and APC. Administration of rhsTM has been
shown to protect rats from TF and endotoxin-induced
DIC or lung injury [89–91]. In addition, rhsTM not only
reduced compression trauma-induced spinal cord injury
by inhibiting leukocyte accumulation and expression of
TNF-α [92] but also provided protection against ischemia-
reperfusion injury in the canine liver [93] and in the rat
kidney [94, 95].
After obtaining promising results in animal experiments,
rhsTM (ART-123, Recomodulin) proceeded to clinical trials.
The eﬃcacy and safety of rhsTM for the treatment of
DIC has been investigated in a multicenter, randomized,
double-blind phase III clinical trial [9]. This clinical trial
was designed to compare rhsTM (0.06mgkg−1 for 30min
once day) with heparin (8Ukg−1 h−1 for 24h) in 234 DIC
patients. Their underlying diseases consisted of infection
and/or hematologic malignancy. During a 6-day course of
treatment, half of the patients received rhsTM, while the
rest received heparin. The DIC resolution rate at day 7 was
signiﬁcantly better in patients receiving rhsTM (66.1%) than
in those receiving heparin (49.9%). The disappearance rate
of bleeding symptoms at day 7 was also better in patients
receiving rhsTM (35.2%) than in those receiving heparin
(20.9%). Remarkably, in DIC resulting from infection,
rhsTM treatment improved the mortality rates at day 28 to
a greater degree than did heparin treatment (rhsTM 28.0%;
heparin 34.6). In the case of DIC resulting from hematologic
malignancy, the mortality rates were 17.2% for the rhsTM
group and 18.0% for the heparin group. Greater decreases
in plasma thrombin-antithrombin complex levels and D-
dimer levels were observed in patients treated with rhsTM.
Importantly, rhsTM treatment showed a better safety proﬁle
with a lower incidence of bleeding-related adverse events. In
2008,rhsTMhasbeenapprovedinJapanforthetreatmentof
DIC. As of May 2011, 4,260 DIC patients (2,588 infections,
1,121 hematologic malignancies, 93 solid tumors, and 458
miscellaneousunderlyingdiseases)weretreatedwithrhsTM,
according to the Asahi Kasei Pharma that has marketed this
drug in Japan.
Importantly,aretrospectivesubanalysisthatfocusedonly
on the 80 patients having infection as the underlying disease
[7] conﬁrmed the usefulness of rhsTM in the treatment of
DIC associated with infection (DIC resolution rates (rhsTM:
67.5%; heparin: 55.6%) and 28-day mortality rates (rhsTM:
21.4%; heparin: 31.6%)). In the USA, a phase II clinical
trial involving 750 patients has been completed as of May
2011thatcomparedrhsTMwithplaceboforthetreatmentof
sepsiswithDIC(NCT00487656),therebyawaitingtheresults
publicized. The Asahi Kasei Pharma America reports that
they will proceed to phase III clinical trials.
7. Concluding Remarks
We are beginning to understand that the crosstalk and
interplay that occur between inﬂammation and coagula-
tion together constitute a critical component driving both
the pathogenesis and progression of sepsis. Therapeutic
approaches targeting both inﬂammation and coagulation
hold great promise for the treatment of patients suﬀering
septic shock. While APC is the ﬁrst to be successfully
administered under a clinical setting, TM is expected to
represent the 2nd generation of eﬀective biologic drugs that
target both inﬂammation and coagulation in septic patients.
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